Evaluation of Madurahydroxylactone as a Slow Release Antibacterial Implant Coating
Muhammad Badar 1, Katherina Hemmen1, Manfred Nimtz1, Martin Stieve2, Meike Stiesch3, Thomas Lenarz 2, Hansjörg Hauser 1, Ute Möllmann 4, Sebastian Vogt 5, Matthias Schnabelrauch 5, Peter P Mueller*, 1
Identifiers and Pagination:Year: 2010
First Page: 263
Last Page: 270
Publisher Id: TOBEJ-4-263
Article History:Received Date: 21/6/2010
Revision Received Date: 9/8/2010
Acceptance Date: 12/8/2010
Electronic publication date: 3/11/2010
Collection year: 2010
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Madurahydroxylactone (MHL), a secondary metabolite with antibacterial activity was evaluated for its suitability to generate controlled drug release coatings on medical implant materials. A smooth and firmly attached layer could be produced from a precursor solution on various metallic implant materials. In physiological salt solutions these coatings dissolved within a time period up to one week. A combination of MHL with a broad spectrum fluoroquinolone antibiotic was used to create a coating that was active against all bacterial strains tested. The time period during which the coating remained active against Pseudomonas aeruginosa was investigated. The results indicated a delayed drug release from single layer coatings in the course of seven days. MHL was biocompatible in cell culture assays and could after a delay even serve as a cell adhesion substrate for human or murine cells. The findings indicate a potential for MHL for the generation of delayed release antimicrobial implant coatings.